Evidence map›Paper›PMID 42737413›Full record

ReviewInternational journal of molecular sciences2026

Vitamin D and COVID-19: Inmunomodulatory Effects and the Mexican Public Health Perspectives.

María Luisa Muñoz-Almaguer, Erick Yair Flores-Salas, Carlos Bancalari-Organista, Raymundo Escutia-Gutierrez, María Virgen-Montelongo, Felipe Alexis Avalos-Salgado, Esmeralda Marisol Franco-Torres, Ana Montserrat Corona-España

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

María Luisa Muñoz-AlmaguerDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.
Erick Yair Flores-SalasDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.ORCID 0009-0004-9770-3884
Carlos Bancalari-OrganistaDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.
Raymundo Escutia-GutierrezDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.ORCID 0000-0002-3072-0987
María Virgen-MontelongoDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.
Felipe Alexis Avalos-SalgadoDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.ORCID 0000-0001-5328-4519
Esmeralda Marisol Franco-TorresDepartment of Pharmacology, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.
Ana Montserrat Corona-EspañaDepartment of Chemistry, University Center of Applied Sciences and Engineering, University of Guadalajara, Guadalajara 44100, Mexico.ORCID 0009-0003-4604-3604

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D is a fat-soluble vitamin, considered a prohormone, that plays a fundamental role in calcium absorption and reabsorption, as well as the modulation of inflammatory response in infectious conditions such as COVID-19. A literature search was conducted in scientific databases and official sources, selecting studies published in the last 10 years in Spanish and English related to vitamin D and COVID-19; studies unrelated to the nutritional approach were excluded to reduce bias and ensure a rigorous and reproducible analysis. It was observed that the probability of contracting COVID-19 increases as the D3 hypovitaminosis prevalence increases. In Mexico, the relevance of vitamin D deficiency or supplementation in this disease has been controversial. Some studies claim that vitamin D supplementation could be a protective factor. According to the National Health Survey in Mexico (Ensanut), the Mexican population has significant deficiencies in this vitamin, contributing to an unfavorable diagnosis, particularly for children and pregnant women, as it is considered a deficiency in the blood when it is below 30 ng/mL and insufficiency when below 20 ng/mL, making these deficiencies important risk factors in the development of COVID-19 severe cases. Nevertheless, the use of vitamin D as an adjuvant agent in the treatment of COVID-19 can represent one of the main options for public health, providing therapeutic properties and health benefits.

Indexed as

COVID-19Vitamin DVitamin D DeficiencyDietary SupplementsFemaleHumansMexicoPandemicsPregnancyPublic HealthVitamin DadjuvantCOVID-19cytokinesSARS-CoV-2 virusVitamin D

Identifiers

PMID42737413
PMCPMC13565868

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.